121 related articles for article (PubMed ID: 17050870)
21. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Reid T; Valone F; Lipera W; Irwin D; Paroly W; Natale R; Sreedharan S; Keer H; Lum B; Scappaticci F; Bhatnagar A
Lung Cancer; 2004 Sep; 45(3):381-6. PubMed ID: 15301879
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
[TBL] [Abstract][Full Text] [Related]
26. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
27. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
[TBL] [Abstract][Full Text] [Related]
28. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.
Jatoi A; Hillman S; Stella P; Green E; Adjei A; Nair S; Perez E; Amin B; Schild SE; Castillo R; Jett JR;
J Clin Oncol; 2005 Dec; 23(36):9113-9. PubMed ID: 16361618
[TBL] [Abstract][Full Text] [Related]
29. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread.
Friedberg JS; Mick R; Stevenson JP; Zhu T; Busch TM; Shin D; Smith D; Culligan M; Dimofte A; Glatstein E; Hahn SM
J Clin Oncol; 2004 Jun; 22(11):2192-201. PubMed ID: 15169808
[TBL] [Abstract][Full Text] [Related]
31. Bexarotene ligand pharmaceuticals.
Hurst RE
Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
[TBL] [Abstract][Full Text] [Related]
32. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
Rinehart J; Adjei AA; Lorusso PM; Waterhouse D; Hecht JR; Natale RB; Hamid O; Varterasian M; Asbury P; Kaldjian EP; Gulyas S; Mitchell DY; Herrera R; Sebolt-Leopold JS; Meyer MB
J Clin Oncol; 2004 Nov; 22(22):4456-62. PubMed ID: 15483017
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients.
Sun AS; Yeh HC; Wang LH; Huang YP; Maeda H; Pivazyan A; Hsu C; Lewis ER; Bruckner HW; Fasy TM
Nutr Cancer; 2001; 39(1):85-95. PubMed ID: 11588907
[TBL] [Abstract][Full Text] [Related]
34. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Edelman MJ; Smith R; Hausner P; Doyle LA; Kalra K; Kendall J; Bedor M; Bisaccia S
J Clin Oncol; 2005 Aug; 23(24):5774-8. PubMed ID: 16110034
[TBL] [Abstract][Full Text] [Related]
37. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
38. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
Jänne PA; von Pawel J; Cohen RB; Crino L; Butts CA; Olson SS; Eiseman IA; Chiappori AA; Yeap BY; Lenehan PF; Dasse K; Sheeran M; Bonomi PD
J Clin Oncol; 2007 Sep; 25(25):3936-44. PubMed ID: 17761977
[TBL] [Abstract][Full Text] [Related]
39. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
Freidlin B; Breathnach OS; Johnson BE
Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
[TBL] [Abstract][Full Text] [Related]
40. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]